Mentice AB (MNTC) AI Stock Analysis

• Market Cap: €261.57M
• Dividend Yield: N/A
• Average Volume (3M): 19.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: -6.82%
• EPS Growth: -449.86%
• Country: SE
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 28,125,734
• 10 Day Avg. Volume: 26,429
• 30 Day Avg. Volume: 19,315
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: kr9.50 ▼(-4.81% Downside)

Mentice AB's overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The company's negative profitability and cash flow issues, coupled with a lack of positive valuation metrics, contribute to a low score. The absence of earnings call insights and corporate events further limits potential positive influences on the stock's evaluation.

Mentice AB Business Overview & Revenue Model

Company Description

Mentice AB (MNTC) is a global leader in the development of advanced simulation solutions for medical training and education, primarily focusing on the fields of cardiology and vascular intervention. The company specializes in creating high-fidelity simulation platforms that enable healthcare professionals to practice and refine their skills in a risk-free environment. Mentice's core products include virtual reality-based simulators that replicate real-life medical procedures, allowing clinicians to gain hands-on experience and improve patient outcomes.

How the Company Makes Money

Mentice AB generates revenue through multiple streams, primarily by selling its advanced simulation systems and software licenses to hospitals, medical institutions, and training centers. The company also offers maintenance and support services, which provide a recurring revenue model as clients require ongoing updates and technical assistance. Additionally, Mentice engages in partnerships with medical device manufacturers and educational institutions, enhancing their product offerings and expanding market reach. These collaborations often lead to co-development opportunities and joint marketing efforts, further contributing to the company's earnings.

Mentice AB Financial Statement Overview

Summary

Mentice AB faces financial difficulties with declining revenues, negative profitability, and cash flow challenges. While the company maintains a low leverage ratio, its inability to generate positive returns and cash flow raises concerns about its financial health. Strategic improvements in operational efficiency and cash management are essential for future stability.

Income Statement

Mentice AB's income statement reveals a challenging financial position with declining revenue and negative profit margins. The TTM data shows a revenue decrease of 12.56%, and the net profit margin is significantly negative at -21.44%. Despite a strong gross profit margin of 90.35%, the company struggles with negative EBIT and EBITDA margins, indicating operational inefficiencies.

Balance Sheet

The balance sheet reflects moderate financial stability with a low debt-to-equity ratio of 0.20, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is not explicitly provided, but the overall asset base appears stable.

Cash Flow

Cash flow analysis shows significant challenges, with negative free cash flow growth and a very low operating cash flow to net income ratio. The free cash flow to net income ratio is highly negative, indicating cash flow issues relative to net losses. The company needs to improve cash generation to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	261.61M	290.33M	273.61M	217.95M	185.06M	137.50M
Gross Profit	236.38M	257.25M	236.38M	188.94M	149.92M	104.11M
EBITDA	-15.78M	18.30M	28.87M	266.00K	1.44M	-3.90M
Net Income	-56.10M	-18.42M	-2.82M	-30.66M	-29.19M	-13.09M
Balance Sheet
Total Assets	268.09M	323.90M	322.53M	332.98M	261.90M	245.27M
Cash, Cash Equivalents and Short-Term Investments	25.47M	53.59M	59.12M	47.28M	12.70M	48.75M
Total Debt	19.25M	9.14M	9.56M	16.68M	14.70M	11.51M
Total Liabilities	172.27M	180.24M	163.55M	170.34M	125.02M	82.02M
Stockholders Equity	95.82M	143.66M	158.97M	162.63M	136.89M	163.25M
Cash Flow
Free Cash Flow	-16.99M	1.48M	29.53M	1.85M	-31.03M	5.20M
Operating Cash Flow	107.00K	17.92M	36.52M	14.91M	-5.13M	30.53M
Investing Cash Flow	-17.10M	-16.44M	-16.18M	-32.28M	-25.90M	-24.97M
Financing Cash Flow	-12.14M	-9.31M	-7.05M	48.99M	-5.78M	-3.98M

Mentice AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Negative. The current price of 9.98 is below the 20-day moving average (MA) of 10.37, below the 50-day MA of 11.98, and below the 200-day MA of 17.33, indicating a bearish trend. The MACD of -0.74 indicates Negative momentum. The RSI at 39.30 is Neutral, neither overbought nor oversold. The STOCH value of 60.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MNTC.

Mentice AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	64 Neutral	€1.11B	43.19	6.93%	―	-5.80%	-65.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRAIN	50 Neutral	€201.70M	―	-26.66%	―	18.37%	34.23%
ACARIX	46 Neutral	€333.06M	―	-106.34%	―	-11.11%	48.03%
CLS.B	43 Neutral	kr188.91M	―	-78.89%	―	57.14%	81.07%
MNTC	42 Neutral	€261.57M	―	-45.57%	―	-6.82%	-449.86%
BACTI.B	40 Underperform	kr595.75M	―	-6.81%	―	11.60%	75.76%